- Previous Close
0.0700 - Open
0.0675 - Bid 0.0650 x --
- Ask 0.0700 x --
- Day's Range
0.0650 - 0.0750 - 52 Week Range
0.0100 - 0.1000 - Volume
229,258 - Avg. Volume
247,996 - Market Cap (intraday)
16.05M - Beta (5Y Monthly) -0.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers. It also develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. In addition, the company operates T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
biovaxys.com--
Full Time Employees
October 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: BIOV.CN
View More
Performance Overview: BIOV.CN
Trailing total returns as of 2024-11-01, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOV.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOV.CN
View MoreValuation Measures
Market Cap
16.05M
Enterprise Value
15.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.36%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.63M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
490.85k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.61M